# **Product** Data Sheet

## Pheophorbide A

Cat. No.: HY-125665 CAS No.: 15664-29-6 Molecular Formula:  $C_{35}H_{36}N_4O_5$ Molecular Weight: 592.68 Target: **Apoptosis** Pathway: Apoptosis

Storage: Powder -20°C 3 years

> In solvent -80°C 6 months -20°C 1 month

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 2 mg/mL (3.37 mM; ultrasonic and warming and heat to 60°C) Methanol: < 1 mg/mL (ultrasonic; warming; heat to 60°C) (insoluble)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.6873 mL	8.4363 mL	16.8725 mL
	5 mM			
	10 mM			

Please refer to the solubility information to select the appropriate solvent.

#### **BIOLOGICAL ACTIVITY**

Description	Pheophorbide A is an intermediate product in the chlorophyll degradation pathway. Pheophorbide A can be used as a photosensitizer. Pheophorbide A is a lymphatic vascular activator. Pheophorbide A has antitumor activity. Pheophorbide A can be used for human lymphatic vascular insufficiencies research <sup>[1][2][3]</sup> .
In Vitro	Pheophorbide A ( $10 \mu\text{M}$ ) increases lymphatic endothelial cells (LECs) sprouting, proliferation and tube formation <sup>[1]</sup> . Pheophorbide A-mediated photodynamic therapy (Pa-PDT) inhibits cellular growth on Hep3B, in a dose-dependent manner with an IC <sub>50</sub> of 1.5 $\mu$ M <sup>[2]</sup> . Pheophorbide A ( $2 \mu$ M, 24 h) induces apoptosis in Hep3B cells after photo-activation <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Pheophorbide A-mediated photodynamic therapy (Pa-PDT) (10 mg/kg (i.v.) or 30 mg/kg (i.p.)) significantly inhibits tumor growth in C3H mouse model with subcutaneous injection of AT-84 cells <sup>[3]</sup> .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male immunocompetent C3H mouse (six-week-old, inoculated subcutaneously with AT-8 cells) <sup>[3]</sup>	
Dosage:	10 mg/kg intravenous (i.v.) or a 30 mg/kg intraperitoneal (i.p.) injection	
Administration:	IV or IP; after 24 h, PDT was performed	
Result:	Pa-PDT, especially i.v. Pa-PDT, significantly inhibited tumor growth up to 70%, while to i.p. Pa-PDT-induced inhibition was up to 43.4% relative to the control group at the enception.	

#### **REFERENCES**

- [1]. Jihye Kim, et al. Pheophorbide a identified in an Eupatorium perfoliatum extract is a novel lymphatic vascular activator. Biomed Pharmacother. 2022 Mar;147:112664.
- [2]. Tang PM, et al. Pheophorbide a, an active compound isolated from Scutellaria barbata, possesses photodynamic activities by inducing apoptosis in human hepatocellular carcinoma. Cancer Biol Ther. 2006 Sep;5(9):1111-6.
- [3]. Ahn MY, et al. Pheophorbide a-mediated photodynamic therapy induces apoptotic cell death in murine oral squamous cell carcinoma in vitro and in vivo. Oncol Rep. 2012 Jun;27(6):1772-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: tech@MedChemExpress.com}$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA